ITK 1

Drug Profile

ITK 1

Alternative Names: Personalised peptide vaccine

Latest Information Update: 10 Feb 2016

Price : $50

At a glance

  • Originator Kurume University
  • Developer FUJIFILM Corporation; GreenPeptide
  • Class Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Glioblastoma; Prostate cancer

Most Recent Events

  • 10 Feb 2016 ITK 1 is still in phase III trials for Glioblastoma and Prostate cancer (Second-line therapy or greater) in Japan (SC, Injection)
  • 01 Aug 2013 Phase-III clinical trials in Prostate cancer (hormone-refractory; second-line therapy or greater) in Japan (SC)
  • 03 Jul 2013 ITK 1 licensed to FUJIFILM Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top